Doctor profile · Federal record
Dr. Husna Siddiqui, MD
Rheumatology Physician (CMS: Rheumatology) · Elgin, IL
- NPI 1396108825
- Accepts Medicare
- MIPS 71.0 / 100 · 2023
- 13 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
1550 N Randall RD
Elgin, IL 601237876
(815) 398-9491
fax (815) 381-7498 - Mailing address
-
Po Box 735263
Chicago, IL 606735263
Credentials & registration
- NPI registered
- April 2016 — 10 yrs on file
- Profile last updated
- September 15, 2023
- Year of graduation
- 2013 — 13 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Illinois #036-160548
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1396108825. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
38,074
Distinct HCPCS
10
Medicare allowed
$575,003
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J3262 |
Injection, tocilizumab, 1 mg | 24,080 | 12 | $6 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 6,050 | 14 | $13 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 3,650 | 12 | $42 | |
J0897 |
Injection, denosumab, 1 mg | 1,680 | 24 | $24 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 1,140 | 13 | $33 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 311 | 220 | $127 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 180 | 111 | $91 | |
96375 |
Injection of additional new drug or substance into vein | 135 | 36 | $16 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 105 | 105 | $168 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 93 | 38 | $132 |
In context: peer comparison
Among 2 peers in this city , average services per provider: 2,388. This provider delivers 16× the peer median.Open Payments
Industry payments received
All-time total
$2,689
Transactions
116
Manufacturers
12
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 32 | $856.47 | |
| Amgen Inc. | 33 | $453.78 | |
| Alexion Pharmaceuticals, Inc. | 5 | $323.05 | |
| UCB, Inc. | 15 | $281.67 | |
| Janssen Biotech, Inc. | 8 | $264.63 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $187.80 | |
| Lilly USA, LLC | 6 | $106.57 | |
| GlaxoSmithKline, LLC. | 5 | $89.56 | |
| Novartis Pharmaceuticals Corporation | 3 | $62.00 | |
| PFIZER INC. | 1 | $25.41 | |
| AstraZeneca Pharmaceuticals LP | 1 | $20.46 | |
| Sandoz Inc. | 1 | $17.76 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,038
Patients
385
Total drug cost
$576,809
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 229 | 99 | $1,123 |
| Hydroxychloroquine Sulfate | Generic | 189 | 78 | $11,555 |
| Methotrexate (Methotrexate Sodium) | Brand | 174 | 80 | $8,811 |
| Allopurinol | Generic | 93 | 31 | $1,076 |
| Meloxicam | Generic | 80 | 36 | $487 |
| Colchicine | Generic | 61 | 29 | $4,932 |
| Leflunomide | Generic | 49 | 21 | $4,683 |
| Alendronate Sodium | Generic | 34 | 11 | $303 |
| Humira(Cf) Pen (Adalimumab) | Brand | 27 | 0 | $281,001 |
| Folic Acid | Generic | 21 | 0 | $85 |
Hospital affiliations
Frequently asked questions
What is Dr. Husna Siddiqui's medical specialty?
Dr. Husna Siddiqui practices Rheumatology Physician in Elgin, IL.
Where does Dr. Husna Siddiqui practice?
Dr. Husna Siddiqui practices at 1550 N Randall RD, Elgin, IL 601237876. Office phone: 8153989491.
What is Dr. Husna Siddiqui's NPI?
Dr. Husna Siddiqui's National Provider Identifier (NPI) is 1396108825, issued by NPPES.
Does Dr. Husna Siddiqui accept Medicare assignment?
Yes. Dr. Husna Siddiqui accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Husna Siddiqui commonly perform?
Top Medicare-reported procedures in 2023: Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129). Source: CMS Medicare Physician & Other Practitioners file.